Sodium pentaborate pentahydrate(Sodium pentaborate pentahydrate) - 在研适应症：肥胖，晚期肾细胞癌，创伤和损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

肿瘤内分泌与代谢疾病泌尿生殖系统疾病+ [1]

在研适应症

肥胖晚期肾细胞癌创伤和损伤

非在研适应症-

原研机构

Bezmialem Vakif University

在研机构

Tabriz University of Medical SciencesIstanbul Education Research HospitalBezmialem Vakif University

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

9

项与 Sodium pentaborate pentahydrate 相关的临床试验

NCT05741606 / Not yet recruiting临床1/2期IIT

Evaluation of the Safety and Efficacy and of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity: a Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial

This study investigates the safety and efficacy of sodium pentaborate pentahydrate in improving the body weight and glycemic profile of patients with overweight or obesity compared to the placebo group.

开始日期2023-07-21

申办/合作机构

Tabriz University of Medical Sciences

NCT05798455 / Not yet recruiting临床1/2期IIT

Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma: An Open-label Single-arm Phase 1b/2 Trial

This study investigates the safety and efficacy of sodium pentaborate pentahydrate in patients with advanced renal cell carcinoma.

开始日期2023-05-22

申办/合作机构

Tabriz University of Medical Sciences

IRCT20220614055167N3 / Suspended临床1/2期IIT

Evaluation of the safety and efficacy and of sodium pentaborate pentahydrate in people with overweight and obesity: a randomised, double-blind, placebo-controlled phase 1/2 trial

开始日期2023-03-21

申办/合作机构

Tabriz University of Medical Sciences

100 项与 Sodium pentaborate pentahydrate 相关的临床结果

登录后查看更多信息

100 项与 Sodium pentaborate pentahydrate 相关的转化医学

登录后查看更多信息

100 项与 Sodium pentaborate pentahydrate 相关的专利（医药）

登录后查看更多信息

28

项与 Sodium pentaborate pentahydrate 相关的文献（医药）

2024-03-01·Biological Trace Element Research

Sodium Pentaborate Prevents Acetaminophen-Induced Hepatorenal Injury by Suppressing Oxidative Stress, Lipid Peroxidation, Apoptosis, and Inflammatory Cytokines in Rats

Article

作者: Kucukler, Sefa ; Kandemir, Fatih Mehmet ; Utlu, Necati ; Aktas Senocak, Esra ; Kurt, Seyda

Acetaminophen (N-acetyl-p-aminophenol, APAP, or paracetamol) is one of the drugs that may be damaging to the kidneys and liver when used in excess. In this context, it is vital to treat these side effects on the liver and kidneys with various antioxidants. Diseases have been treated using herbal and mineral remedies since ancient times. The mineral boron, found in rocks and water, is a crucial ingredient with multiple positive biological effects. The primary objective of this research is to determine whether or not boron has a protective effect against the toxicity generated by APAP in rats. Male Sprague-Dawley rats were pretreated orally with boron-source sodium pentaborate (B50 and B100 mg/kg) for 6 days by gastric gavage in order to counteract the toxicity caused by a single dose of APAP (1g/kg). APAP increased lipid peroxidation as well as serum BUN, creatinine concentrations, and serum activities of AST, ALP, and ALT by consuming GSH in liver and kidney tissues. In addition, the activity of antioxidative enzymes, including SOD, CAT, and GPx, was diminished. Inflammatory indicators such as TNF-α, IL-1β, and IL-33 were elevated in conjunction with APAP toxicity. In kidney and liver tissues, APAP dramatically increased the activity of caspase-3 and triggered apoptosis. Sodium pentaborate therapy on a short-term basis reduced biochemical levels despite these effects of APAP. This study showed that boron protects rats from the harmful effects of APAP by acting as an anti-inflammatory, antioxidant, and anti-apoptotic agent.

2024-03-01·Heliyon

The efficacy of topical sodium pentaborate formulation on hemorrhoid disease: A randomized, double-blind, placebo-controlled trial

Article

作者: Pirouzpanah, Mohammad-Bagher ; Alihosseini, Samin ; Gharekhani, Afshin ; Ayşan, Erhan ; Khoshbaten, Manouchehr ; Sarbakhsh, Parvin ; Doğan, Ayşegül ; Şahin, Fikrettin ; Farshbaf-Khalili, Azizeh ; Pirouzpanah, Mohammad Sadegh

BackgroundThe topical application of boron has been significantly associated with intensifying wound healing. Using 3% boric acid in deep wounds significantly contributes to wound healing and reduces the duration of hospitalization in the intensive care. The objective of this study was to assess the therapeutic impact of a topical gel containing sodium pentaborate pentahydrate on the management of wounds resulting from grade 1 to 3 hemorrhoids.MethodsIn this randomized double-blind placebo-controlled trial, we applied a topical gel consisting of sodium pentaborate pentahydrate 3% on 206 eligible patients with the diagnosis of grade 1, 2, and 3 hemorrhoid diseases. Then patients were randomly allocated to two groups of sodium pentaborate pentahydrate or placebo gel with a ratio of 1:1 and received the allocated gel for four weeks. Patient hemorrhoid symptoms severity, hemorrhoid degree, and anoscopy findings were compared before and after the trial.ResultsBefore the intervention, symptom severity (p > 0.05) and anoscopy findings (p = 0.815) were similar between the two groups. Subsequent to the intervention, a majority of patients in the intervention group experienced a reduction in anal itching compared to the placebo group [adjusted mean difference (aMD) 95% CI: -1.98 (-2.2 to -1.8), p = 0.007]. Moreover, resting pain [aMD (95% CI): -1.37 (-1.6 to -1.1), p = 0.015], pain during defecation [aMD (95% CI): -2.19 (-2.4 to -2.0), p = 0.005], feeling a lump in the anus (aMD (95% CI): -0.71 (-1.2 to -0.2), p = 0.011), bleeding during defecation (41.7% vs. 66.9%, p = 0.027), and hemorrhoid degree (p < 0.001) in the intervention group was less than the placebo group.ConclusionOur findings indicate the effectiveness of the study gel on hemorrhoid symptoms and anoscopy findings in patients.

2023-09-01·Journal of Trace Elements in Medicine and Biology

The effect of the boron-based gel on the treatment of diabetic foot ulcers: A prospective, randomized controlled trial

Article

作者: Farshbaf-Khalili, Azizeh ; Ayşan, Erhan ; Pirouzpanah, Mohammad Bagher ; Demirci, Selami ; Mobasseri, Majid ; Şahin, Fikrettin ; Doğan, Ayşegül ; Ostadrahimi, Alireza

BACKGROUNDChronic ulcers represent impaired healing capacity with high mortality in the elderly or patients with systemic disorders such as diabetes. Boron is an effective agent in wound healing by promoting cell migration and proliferation and reducing inflammation in the wound area. This study aimed to evaluate the therapeutic effect of a sodium pentaborate-based topical formulation compared to control on the treatment of diabetic foot ulcers.METHODSA prospective, double-blind, randomized controlled trial was conducted to apply randomly the topical sodium pentaborate 3% gel or topical conventional remedy (control) by patients diagnosed with diabetic foot ulcers. The 171 eligible participants aged 18-75 years received the allocated medicines twice a day for a month with an allocation ratio of 3:1. Twenty-five days and two months after the end of the trial, participants were reinvestigated for their ulcer condition and any recurrence. Wagner's classification of diabetic foot ulcers was applied to this purpose (0-5).RESULTS161 participants (57 females, 104 males; mean age: 59.37) completed this study. After the intervention, most participants in the intervention group had a lower ulcer grade than the control group (adjusted mean difference (95% CI): - 0.91 (-1.1 to -0.73); p < 0.001). Moreover, most participants in the intervention group (n = 109 (90.8%)) were treated at a higher rate than the control group (n = 5 (12.2%)) after intervention (adjusted odds ratio (95% CI): 0.008 (0.002-0.029); p < 0.001). There was no case of recurrence in the intervention group while its rate was (n = 2 (40%)) in the control group (p < 0.001).CONCLUSIONThe present study suggests that topical sodium pentaborate gel may help treat and decrease the grade of diabetic foot ulcers and prevent the recurrence of diabetic foot ulcers.

100 项与 Sodium pentaborate pentahydrate 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床2期	伊朗	Tabriz University of Medical Sciences	2023-07-21
晚期肾细胞癌	临床2期	伊朗	Tabriz University of Medical Sciences	2023-05-22
创伤和损伤	临床1期	-	Bezmialem Vakif University	-
创伤和损伤	临床1期	-	Istanbul Education Research Hospital	-